Table 31: Chronic Heart Failure
Therapeutics Market - Discovery Pipeline, 2011 47
They assessed chronic heart failure
survival time in a metaanalysis of nine prospective randomized control trials comparing exercise with usual care in 801 subjects.
Following this study will be safety and efficacy studies in chronic heart failure
and oncology indications.
Oral CoQ10 improved the heart's functional capacity, the ability of key blood vessels to dilate, and the contractility of the heart's left ventricle in patients with stable chronic heart failure
In 2004, Vasogen was granted the CE Mark for its Celacade technology for the treatment of chronic heart failure
, providing regulatory approval for the 25 member countries of the European Union.
Chronic heart failure
is recognized as a major and escalating public health problem in industrialized countries with aging populations.
Barostim neo is a second-generation device that uses CVRx-patented technology designed to trigger the body's own natural blood flow regulation system to treat patients suffering from chronic heart failure
f]T morbi-mortality clinical study demonstrated that Procoralan has the potential to not only improve clinical outcomes for patients with chronic heart failure
but in addition could also improve physical and emotional wellbeing.
Health professionals may need to improve current practices to better treat anemia in patients with chronic heart failure
," says Dr.
He noted that this is the second large clinical trial that has failed to show a mortality benefit for statin therapy in patients with symptomatic chronic heart failure
Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chronic Heart Failure
Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
ResMed is working with global regulatory authorities to proactively revise the labels and instructions for use for ResMed ASV devices to include a contraindication for people with symptomatic chronic heart failure
(with left ventricular ejection fraction, LVEF, less than or equal to 45 percent).
ivabradine), presented today at the European Society of Cardiology congress, are clinically important as quality of life is greatly impaired in patients with chronic heart failure
and poor quality of life in these patients is associated with worse disease outcomes.
The Centers for Medicare and Medicaid Services has denied national coverage of nesiritide (Natrecor) for patients with chronic heart failure
That's why Yusuf's team is now testing enalapril's ability to prevent chronic heart failure
in people with some damage to the heart but not symptoms of long-term heart failure.